 |
 |
| DISSS Home | Contact Us |
| ||||||||
|
|
|
|
|
|
| ||
|
|
| ||||||
.gif){kind=spacer} 
|
|
|
|||||||||||||||||||||||||||||||||||||||
|
|
||||||||||||||||||||||||||||||
|
| ||||||||||||||||||||||||||||||
Clinical Description
Staphylococcus aureus can produce a variety of syndromes with clinical manifestations including skin and soft tissue lesions, empyema, pyarthrosis, bloodstream infection, pneumonia, osteomyelitis, septic arthritis, endocarditis, sepsis, and meningitis.
Laboratory Criteria
1) Isolation of Staphylococcus aureus from any body site.
AND
2) Intermediate or high-level resistance of the Staphylococcus aureus isolate
to vancomycin, detected and defined according to NCCLS* approved standards
and recommendations (MIC: 8-16 µg/ml for VISA and MIC:≥32 µg/ml
for VRSA).
Case Classification
Confirmed: A clinically compatible case of vancomycin-intermediate or vancomycin-resistant Staphylococcus aureus that is laboratory-confirmed (MIC: 8-16 µg/ml for VISA and MIC: ≥32 µg/ml for VRSA).
Comment
Data to be collected: A standardized data collection form should be used
for all reported vancomycin-intermediate or vancomycin-resistant Staphylococcus
aureus through the National Notifiable Diseases Surveillance System.
* National Committee for Clinical Laboratory Standards
References
NCCLS. (2003) Methods for dilution antimicrobial susceptibility tests
for bacteria that grow aerobically; Approved standard 6th ed., vol.
23, No. 2. Approved standard M7-A5. NCCLS, Wayne, Pa.
NCCLS. (2003) Performance standards for antimicrobial susceptibility
testing; Thirteenth informational supplement M100-S13 (M7). NCCLS, Wayne,
Pa.
 |
|
|
|
|
Privacy Policy | Accessibility CDC Home | Search | Health Topics A-Z This page last updated January 9, 2008 United States
Department of Health and Human Services "Epi Info" is a trademark of the Centers for Disease Control and Prevention (CDC). |
